	US 12,403,172 B2
	Composition for preventing, alleviating or treating metabolic syndrome accompanied by obesity and/or diabetes, containing, as active ingredient, complex (IB complex) of Indian gooseberry extract and sprout barley extract
Hae-Yeon Lee, Gyeonggi-do (KR); Jong-Lae Kim, Gyeonggi-do (KR); Tae-Gi Kim, Gyeonggi-do (KR); Mi-Ryeong Park, Gyeonggi-do (KR); Jong-Wook Lee, Seoul (KR); and Jin-Seong Yang, Gyeoenggi-do (KR)
Assigned to HLSCIENCE CO., LTD, Gyeonggi-Do (KR)
Appl. No. 17/614,749
Filed by HLSCIENCE CO., LTD, Gyeonggi-do (KR)
PCT Filed May 19, 2020, PCT No. PCT/KR2020/006545 § 371(c)(1), (2) Date Nov. 29, 2021, PCT Pub. No. WO2020/242113, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 10-2019-0064098 (KR), filed on May 30, 2019.
Prior Publication US 2022/0226421 A1, Jul. 21, 2022
Int. Cl. A61K 36/8998 (2006.01); A23L 33/105 (2016.01); A61K 36/185 (2006.01); A61P 3/08 (2006.01)

CPC A61K 36/8998 (2013.01) [A23L 33/105 (2016.08); A61K 36/185 (2013.01); A61P 3/08 (2018.01)]

7 Claims

1. A method for prevention, improvement or treatment of metabolic syndrome, comprising:

administering a complex of Indian gooseberry (Emblica officinalis) extract and barley sprout (Hordeum vulgare) extract as an active ingredient to a subject in need thereof,

wherein the weight ratio of Indian gooseberry extract to barley sprout extract is 4:1 to 1:1,

wherein the metabolic syndrome is obesity,

wherein the Indian gooseberry extract comprises 1 to 5 mg/g of ellagic acid under the condition of acid hydrolysis, or 5 to 25 mg/g of free ellagic acid under the condition of no acid hydrolysis, and

wherein the barley sprout extract comprises 6 to 11 mg/g of saponarin.